Triple-negative breast cancer: current management and future options
نویسندگان
چکیده
منابع مشابه
Management Options in Triple-Negative Breast Cancer
Notorious for its poor prognosis and aggressive nature, triple-negative breast cancer (TNBC) is a heterogeneous disease entity. The nature of its biological specificity, which is similar to basal-like cancers, tumors arising in BRCA1 mutation carriers, and claudin-low cancers, is currently being explored in hopes of finding the targets for novel biologics and chemotherapeutic agents. In this re...
متن کاملFuture of Triple Negative Breast Cancer: Can Immunotherapy Treat This Deadly Subtype of Breast Cancer?
Triple negative breast cancer (TNBC): challenges and solutions via the immune cells TNBC is one of the most complicated types of breast cancer to treat. It is generally diagnosed based on the absence of three receptors: estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) and is thus defined as a triple negative. TNBC is often more aggressive with lower survival rates...
متن کاملTriple-negative breast cancer--current status and future directions.
Triple-negative breast cancer (TNBC) is defined by a lack of expression of both estrogen and progesterone receptor as well as human epidermal growth factor receptor 2. It is characterized by distinct molecular, histological and clinical features including a particularly unfavorable prognosis despite increased sensitivity to standard cytotoxic chemotherapy regimens. TNBC is highly though not com...
متن کاملTriple-Negative Breast Cancer: Adjuvant Therapeutic Options
Triple-negative breast cancer (TNBC), a subtype distinguished by negative immunohistochemical assays for expression of the estrogen and progesterone receptors (ER/PR) and human epidermal growth factor receptor-2(HER2) represents 15% of all breast cancers. Patients with TNBC generally experience a more aggressive clinical course with increased risk of disease progression and poorer overall survi...
متن کاملTriple-Negative Breast Cancer: Frequency, Molecular Subtypes, and Therapeutic Options
INT RO DUC TI ON Breast cancer is the most common malignancy in women. An estimated 1 million cases of breast cancer are diagnosed annually worldwide and 400.000 patients die from the disease every year[1]. Multiple oncogenes, tumor suppressor genes, and sex steroid hormones and their receptors are involved in the genesis and development of breast cancer. Breast cancer is a heterogeneous malign...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Cancer Supplements
سال: 2009
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(09)70005-9